There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Haemonetics (HAE) and uniQure (QURE) with bullish sentiments.
Haemonetics (HAE)
Needham analyst Michael Matson assigned a Buy rating to Haemonetics today and set a price target of $132.00. The company’s shares closed last Thursday at $110.58.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 6.6% and a 58.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Haemonetics with a $131.75 average price target.
See today’s analyst top recommended stocks >>
uniQure (QURE)
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure today and set a price target of $105.00. The company’s shares closed last Thursday at $63.02.
According to TipRanks.com, Amusa is a top 100 analyst with an average return of 27.2% and a 53.5% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Axovant Gene Therapies, and Catalyst Biosciences.
Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $86.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
